Patients who had adjuvant Verzenio with endocrine therapy had a small but significant improvement in survival versus endocrine therapy alone.

Kite has paid $120 million upfront to Pregene to gain certain license rights and to collaborate on developing in vivo cell therapies with the Shenzhen, China-based firm. Pregene is entitled to receive ...

The agency launched the Commissioner's National Priority Voucher pilot program to quickly approve products that could address national interests.

Trial initiation triggered a $250 million payment to SystImmune from Bristol Myers Squibb, under a 2023 collaboration and license agreement.

In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...

Patients with a very rare immune disorder who have gotten the gene therapy have experienced sustained long-term immune ...

The funding includes an initial tranche of $7.5 million in equity and technical support, and the biotech and the foundation will form a joint steering committee.

NEW YORK – Akari Therapeutics on Wednesday said it hopes to raise $2.5 million by selling 3,125,000 American depositary shares (ADS) in a registered direct offering.

Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.

The firm amended the terms of a deal with Pfizer and submitted results from the BREAKWATER trial of Braftovi, Erbitux, and chemo against chemo alone.

The firm continues to seek needed funds to launch a Phase I/II trial of ELP-02 for this extremely rare form of ...

The trial, performed at Radboud University Medical Center, will test TGW211, which involves a trigger designed to limit off-target effects of the radioactive material.